As per deal, Lundbeck is handing over $123 million and committing to about a billion dollars more in milestones — with more than half of that tied to sales goals.
Lundbeck is spending its money on a single asset being studied by Prexton : foliglurax.
Foliglurax is an investigative treatment being developed by Prexton Therapeutics for the treatment of PD.
endpts.com/lundbeck-bags-a-...
The study is expected to be completed in 2018.
They are at least 4 years away from having a drug- if they succeed. Nonetheless, very interesting, and they have a cool diagram of the neural interactions here: prextontherapeutics.com/r_a...
this page and diagram is fascinating
Yay! Lundbeck made Parkensan The treatment based on the piperidine
that we can’t get in the United States boo bad FDA
Are you talking about this
encrypted.google.com/patent...
or
TRADEMARK Parkinsan®
COMPOUND Budipin
FIRST REGISTRATION 1997
REGISTERED NO. OF COUNTRIES 01
Communication with People Suffering Parkinson’s Disease (PD). Some Observations from Pete-1. A Contribution to World PD Awareness Day
Memory, Cognitive Decline, AD, PD & Dementia And A Potential Way To Help Deal With Them Using "LO"
A new May-December relationship with Parkinson´s - Should I deal with him as with someone with no disease NO CONTACT or not?Could a prostate drug slow or stop Parkinson’s?
How do you deal with the dismissive ‘encouraging comments’ from friends and family like “people don’t die of Parkinson’s, you know”?
